Pancreatic cancer is a common malignant tumor of the digestive system, and its incidence is increasing worldwide. The treatment of pancreatic cancer is mainly surgery, but the development of traditional surgery, chemoradiotherapy has entered the plateau stage, and immunotherapy has received more and more attention. Different anesthesia methods, anaesthetic drugs and their preparations have different effects on the perioperative immune function of patients with pancreatic cancer, and even affect the long-term prognosis of patients. Suppression of immune function caused by surgery and anesthesia may promote tumor recurrence and metastasis, thereby affecting the longterm prognosis of patients. The use of propofol intravenous anesthesia during surgery can reduce pro-inflammatory factors and increase anti-inflammatory factors, thereby effectively improving the immune function of perioperative tumor patients. At the same time, using nanoemulsion as a carrier in a drug delivery system can improve the solubility and loading capacity of poorly soluble drugs, and increase the absorption rate and bioavailability of fat-soluble drugs in the body. Therefore, in this study, a combination of propofol nano-injection and remifentanil injection liquid combined with propofol nanoemulsion preparation and propofol injection alone was used in the operation of pancreatic cancer patients. By comparing the two groups of patients Basic indicators during and after surgery, hemorheology levels, lymphocyte subsets, and proinflammatory cytokines, to study the use of the compound propofol nanoemulsion preparation in patients with pancreatic cancer during surgery Effects of immune function. The results showed that compound propofol nanoemulsion can improve the immune function of patients with pancreatic cancer during surgery, reduce the level of inflammatory factors, and has a good prognosis and high safety.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1166/jnn.2021.18661 | DOI Listing |
Arq Bras Cir Dig
January 2025
D'Or Institute for Research and Education, Digestive Surgery Residency Program - Rio de Janeiro (RJ), Brazil.
Liver metastases from melanomas, sarcomas, and renal tumors are less frequent. Treatment and prognosis will depend on whether they are isolated or multiple, size and location, the presence or absence of extrahepatic neoplastic disease, age, stage of the initial disease, initial treatments instituted, time of evolution, and clinical condition of the patient. Recently, a high number of oncological therapies including monotherapy or in combination, neoadjuvants or adjuvants, and immuno-oncological treatments have been developed and tested, increasing disease-free time and survival.
View Article and Find Full Text PDFSci Transl Med
January 2025
Department of Surgery, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Pancreatic ductal adenocarcinoma (PDAC) driven by the mutation presents a formidable health challenge because of limited treatment options. MRTX1133 is a highly selective and first-in-class KRAS-G12D inhibitor under clinical development. Here, we report that the advanced glycosylation end product-specific receptor (AGER) plays a key role in mediating MRTX1133 resistance in PDAC cells.
View Article and Find Full Text PDFJ Mol Med (Berl)
January 2025
Hospital Sensory Department, Shenzhen Qianhai Shekou Free Trade Zone Hospital, 36 Gongye Qi Road, Nanshan District, Shenzhen, 518067, China.
This work researched the influence and mechanism of CD155 on hepatocellular carcinoma advancement. CD155 expression and its effect on survival of hepatocellular carcinoma patients were analyzed based on the GEPIA2 database. String software predicted the interacting between CD155 and CD96, which was further verified by co-immunoprecipitation experiment.
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Hepato-Pancreato-Biliary Surgery and Liver Transplantation, Pôle des Pathologies Digestives et Hépatiques, Hôpital de Hautepierre-Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
J Gastroenterol
January 2025
Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!